Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)

BACKGROUND: Immune checkpoint inhibitors (ICIs) are currently the standard of care for metastatic urothelial cancer (mUC) after the failure of previous platinum-based chemotherapy. The choice of further therapy after ICI progression is a new challenge, and scarce data support it. We aimed to examine...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Med Insights Oncol
Autors principals: Bersanelli, Melissa, Buti, Sebastiano, Cortellini, Alessio, Bandini, Marco, Banna, Giuseppe Luigi, Pederzoli, Filippo, Farè, Elena, Raggi, Daniele, Giannatempo, Patrizia, De Giorgi, Ugo, Basso, Umberto, Losanno, Tania, Santini, Daniele, Mucciarini, Claudia, Tucci, Marcello, Tambaro, Rosa, Farnesi, Azzurra, Caffo, Orazio, Veccia, Antonello, Naglieri, Emanuele, Briganti, Alberto, Procopio, Giuseppe, Pignata, Sandro, Necchi, Andrea
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2021
Matèries:
Original Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8274126/
https://ncbi.nlm.nih.gov/pubmed/34290538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/11795549211021667
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars